

John F Forbes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10586865/publications.pdf>

Version: 2024-02-01

96
papers

16,324
citations

109264

35
h-index

243529

44
g-index

104
all docs

104
docs citations

104
times ranked

14139
citing authors

#	ARTICLE	IF	CITATIONS
1	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , 2013, 24, 2206-2223.	0.6	2,805
2	Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. <i>Lancet</i> , The, 2013, 381, 805-816.	6.3	1,664
3	A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer. <i>New England Journal of Medicine</i> , 2005, 353, 2747-2757.	13.9	1,465
4	Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015, 26, 1533-1546.	0.6	1,449
5	Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. <i>Lancet Oncology</i> , The, 2010, 11, 1135-1141.	5.1	1,017
6	Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. <i>Lancet Oncology</i> , The, 2008, 9, 45-53.	5.1	929
7	Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98. <i>Journal of Clinical Oncology</i> , 2007, 25, 486-492.	0.8	835
8	Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4273-4278.	0.8	666
9	Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer—96-Month Follow-up of the Randomized IBIS-I Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 272-282.	3.0	510
10	Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. <i>Lancet</i> , The, 2014, 383, 1041-1048.	6.3	504
11	Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy. <i>New England Journal of Medicine</i> , 2015, 372, 923-932.	13.9	452
12	Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 766-776.	13.9	448
13	Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. <i>Journal of Clinical Oncology</i> , 2016, 34, 927-935.	0.8	390
14	Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. <i>Lancet Oncology</i> , The, 2011, 12, 1101-1108.	5.1	356
15	Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. <i>Lancet Oncology</i> , The, 2015, 16, 67-75.	5.1	349
16	Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 3411-3415.	0.8	271
17	Preventive therapy for breast cancer: a consensus statement. <i>Lancet Oncology</i> , The, 2011, 12, 496-503.	5.1	196
18	Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. <i>Lancet Oncology</i> , The, 2008, 9, 866-872.	5.1	186

#	ARTICLE	IF	CITATIONS
19	Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. <i>Journal of Clinical Oncology</i> , 2016, 34, 2452-2459.	0.8	178
20	Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value. <i>Nature Communications</i> , 2015, 6, 5899.	5.8	162
21	Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. <i>Lancet</i> , The, 2016, 387, 866-873.	6.3	149
22	Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 1117-1124.	0.8	134
23	Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 1972-1979.	0.8	133
24	Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. <i>Lancet</i> , The, 2020, 395, 117-122.	6.3	128
25	Cardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen: Safety Analysis of BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 5715-5722.	0.8	125
26	Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 709-717.	0.8	110
27	Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3967-3975.	0.8	108
28	Nerve fibers infiltrate the tumor microenvironment and are associated with nerve growth factor production and lymph node invasion in breast cancer. <i>Molecular Oncology</i> , 2015, 9, 1626-1635.	2.1	105
29	Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. <i>Journal of the National Cancer Institute</i> , 2019, 111, 210-213.	3.0	70
30	Influence of Comorbidities and Age on Risk of Death Without Recurrence: A Retrospective Analysis of the Arimidex, Tamoxifen Alone or in Combination Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 4266-4272.	0.8	61
31	Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 1460-1468.	5.1	56
32	Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 727-734.	1.1	47
33	Adjuvant ovarian function suppression and cognitive function in women with breast cancer. <i>British Journal of Cancer</i> , 2016, 114, 956-964.	2.9	38
34	Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options. <i>Supportive Care in Cancer</i> , 2016, 24, 2139-2146.	1.0	38
35	Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12â€™93. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 491-500.	1.1	37
36	Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2763-2770.	3.2	36

#	ARTICLE	IF	CITATIONS
37	Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 139-143.	0.8	30
38	HER2 status predicts for upfront AI benefit: AÂTRANS-AIOG meta-analysis of 12,129 patients fromÂATAC, BIG 1-98 and TEAM with centrally determined HER2. <i>European Journal of Cancer</i> , 2017, 79, 129-138.	1.3	21
39	Long-Term Effects of Adjuvant Chemotherapy in Breast Cancer. <i>Acta OncolÃ³gica</i> , 1992, 31, 243-250.	0.8	17
40	The Use of Early Adjuvant Aromatase Inhibitor Therapy: Contributions From the BIG 1-98 Letrozole Trial. <i>Seminars in Oncology</i> , 2006, 33, 2-7.	0.8	7
41	Choosing between Endocrine Therapy and Chemotherapy â€œ or is there a Role for Combination Therapy?. <i>Breast Cancer Research and Treatment</i> , 2002, 75, 37-44.	1.1	5
42	Patient-level meta-analysis of randomized trials of aromatase inhibitors (AI) versus tamoxifen (Tam).. <i>Journal of Clinical Oncology</i> , 2014, 32, 529-529.	0.8	5
43	Kidney Cancer. , 0, , 333-345.		4
44	Cancer of the Uterine Corpus. , 0, , 394-401.		3
45	Ovarian and Fallopian Tube Cancers. , 0, , 377-393.		3
46	Personalization of loco-regional care for primary breast cancer patients (part 2). <i>Future Oncology</i> , 2015, 11, 1301-1305.	1.1	3
47	10-year analysis of the ATAC trial: wrong conclusion? â€œ Authors' reply. <i>Lancet Oncology</i> , The, 2011, 12, 217.	5.1	2
48	Testicular Germ Cell Cancer. , 0, , 365-373.		1
49	Central Nervous System Tumours. , 0, , 561-578.		1
50	Primary Cutaneous T-Cell Lymphoma. , 0, , 498-517.		1
51	Cancer of the Prostate. , 0, , 354-359.		1
52	The Treatment of Cancers of the Small Bowel. , 0, , 273-283.		1
53	The Treatment of Carcinoma of the Colon and Rectum. , 0, , 284-324.		1
54	Cancer of the Cervix and Vagina. , 0, , 402-410.		1

#	ARTICLE	IF	CITATIONS
55	Is Cancer Risk Reduced by a Health-Enhancing Diet?. , 0 , 53-58.		0
56	Principles and Practice of "Critical Appraisal" , 0 , 1-1.		0
57	Soft Tissue Sarcoma. , 0 , 539-557.		0
58	Breast Cancer Prevention Trials. , 0 , 48-52.		0
59	Treating Gynaecological Tumours. , 0 , 375-376.		0
60	Screening for Ovarian Cancer. , 0 , 144-150.		0
61	Treating Tumours of the Respiratory System. , 0 , 201-202.		0
62	Which Interventions Help Individuals to Stop Smoking?. , 0 , 43-47.		0
63	Screening for Lung Cancer. , 0 , 164-171.		0
64	Treating Sarcomas. , 0 , 537-538.		0
65	Treating Tumours of the Gastrointestinal Tract. , 0 , 231-232.		0
66	Treating Skin Cancer. , 0 , 465-466.		0
67	Appraising Clinical Literature in Cancer. , 0 , 3-16.		0
68	Screening for Stomach Cancer. , 0 , 172-187.		0
69	Treating Breast Cancer. , 0 , 427-428.		0
70	Can Lifestyle Behaviour Change Reduce the Risk and Incidence of Urological Cancers?. , 0 , 87-100.		0
71	Cervical Screening. , 0 , 118-132.		0
72	Ocular Adnexal and Orbital Tumours. , 0 , 586-595.		0

#	ARTICLE	IF	CITATIONS
73	Treating Vulval Cancer. , 0 , 411-418.		0
74	Cutaneous Melanoma. , 0 , 467-476.		0
75	Do Sunscreens Reduce the Incidence of Skin Cancers?. , 0 , 76-86.		0
76	Treating Tumours of the Urogenital System. , 0 , 331-332.		0
77	Treating Cancers of the Eye and Associated Structures. , 0 , 579-580.		0
78	What is the Role of Prophylactic Surgery in the Prevention of Colorectal Cancer?. , 0 , 101-106.		0
79	Screening for Prostate Cancer. , 0 , 133-143.		0
80	Gastric Carcinoma. , 0 , 243-246.		0
81	Understanding the Concepts Behind Health Economics. , 0 , 25-33.		0
82	Cancer of the Oesophagus. , 0 , 233-242.		0
83	Treatment of Anal Cancer. , 0 , 225-330.		0
84	Do Primary and Secondary Prevention Interventions for Sun Protection Reduce the Risk of Skin Cancers?. , 0 , 68-75.		0
85	Screening for Cancers. , 0 , 107-107.		0
86	Hepatobiliary Cancers. , 0 , 267-272.		0
87	Uveal Melanoma. , 0 , 581-585.		0
88	Malignant Pleural Mesothelioma. , 0 , 224-229.		0
89	Kaposi's Sarcoma. , 0 , 518-536.		0
90	Treating Central Nervous System Tumours. , 0 , 559-560.		0

#	ARTICLE	IF	CITATIONS
91	Cancer of the Penis. , 0, , 360-364.		0
92	Screening for Melanoma. , 0, , 188-200.		0
93	Treatment of Basal Cell Carcinoma. , 0, , 477-491.		0
94	Finding the "Best Evidence" for Cancer Care. , 0, , 17-24.		0
95	Cancer Prevention. , 0, , 39-41.		0
96	Cancer of the Bladder. , 0, , 346-353.		0